Eloxx Pharmaceuticals (ELOX) Stock Statistics & Valuation Metrics

Eloxx Pharmaceuticals has a market cap or net worth of $330.00. The enterprise value is ―.

Eloxx Pharmaceuticals has 3,300,528 shares outstanding. The number of shares has decreased by -2.65% in one year.

Eloxx Pharmaceuticals’s return on equity (ROE) is 3.38 and return on invested capital (ROIC) is -1263.55%.

The current PE Ratio of Eloxx Pharmaceuticals is ―. Eloxx Pharmaceuticals’s PEG ratio is 0.00194.

In the last 12 months, Eloxx Pharmaceuticals had revenue of 0.00 and earned -36.06M in profits. Earnings per share was -16.65.

In the last 12 months, operating cash flow was -17.99M and capital expenditures 0.00, giving a free cash flow of -17.99M billion.

Eloxx Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Eloxx Pharmaceuticals upcoming earnings date is Nov 7, 2024, TBA (Confirmed).

Eloxx Pharmaceuticals as a current ratio of 0.87, with Debt / Equity ratio of -125.55%

In the past 12 months, Eloxx Pharmaceuticals has paid 0.00 in taxes.

Eloxx Pharmaceuticals EV to EBITDA ratio is 0.06, with an EV/FCF ratio of 0.06.

Eloxx Pharmaceuticals has $4.78M in cash and marketable securities with $5.76M in debt, giving a net cash position of -$983.00K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Eloxx Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―